Read our latest updates & insights

The Big Molecule Watch reports that a US District Court Judge ruled AbbVie’s conduct in relation to its blockbuster Humira® (adalimumab), while preventing competitors from reaching the market in the US, was not illegal. The action was filed against AbbVie by a number ...

Xbrane Pharma announced that it has entered into an agreement with Akademiska Hus for the lease of new premises at Campus Solna. From March 2021, Xbrane will establish a new development lab for biosimilars and will move their headquarters to the new campus at Solna. Xbrane ...

The Coalition for Epidemic Preparedness Innovations, CSL and the University of Queensland announced they have entered into a partnering agreement to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate.

Mylan and Lupin announce EMA marketing authorisation for Nepexto® (etanercept) for all indications of the reference product Enbrel®.

Bloomberg Law reports on the ongoing US Court of Appeals for the Federal Circuit dispute between Genentech and Amgen regarding bevacizumab. In a hearing on 3 June 2020, Genentech asked the Court to prevent Amgen selling its biosimilar bevacizumab Mvasi® to new patients, des...

Significant biosimilar activities this week include
25 May 20 | The American Journal of Managed Care reported two cost savings studies presented at a virtual meeting of the International Society for Pharmacoeconomics and Outcomes Research.  The studies, which were spo...

LiveMint reported that Aurobindo Pharma announced it would sell its biosimilars business to its wholly owned subsidiary, CuraTeQ Biologics in 2019/20 Q4 earnings call.

Eli Lilly announced that the FDA has approved Taltz® (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis.

Henlius Biotech announces it has received a positive CHMP opinion, recommending marketing authorisation for HLX02 (proposed trastuzumab biosimilar).